open access

Vol 2, No 4 (2016)
Case report
Published online: 2017-02-14
Get Citation

The use of methotrexate in the treatment of selected autoimmune connective tissue diseases — our own experience and review of the literature data

Adriana Polańska, Aleksandra Dańczak-Pazdrowska, Ryszard Żaba, Zygmunt Adamski
Forum Dermatologicum 2016;2(4):165-170.

open access

Vol 2, No 4 (2016)
CASE STUDY
Published online: 2017-02-14

Abstract

Methotrexate (MTX) belongs to the most commonly used immunosuppressants in dermatology. Correct classification of the patient, taking into account possible contraindications may minimize the risk of adverse effects of MTX, while the emergence of new forms for applications of MTX — subcutaneous prefilled syringes — significantly improved bioavailability
compared to oral treatment and allowed to increase the efficacy and safety of the treatment. We present our experience with the use of subcutaneous MTX in the treatment of chronic cutaneous lupus erythematosus (Discoid Lupus Erythematosus, DLE) and in generalized as well as deep forms of morphea. In addition, we reviewed the literature and current guidelines regarding treatment of both diseases.

Abstract

Methotrexate (MTX) belongs to the most commonly used immunosuppressants in dermatology. Correct classification of the patient, taking into account possible contraindications may minimize the risk of adverse effects of MTX, while the emergence of new forms for applications of MTX — subcutaneous prefilled syringes — significantly improved bioavailability
compared to oral treatment and allowed to increase the efficacy and safety of the treatment. We present our experience with the use of subcutaneous MTX in the treatment of chronic cutaneous lupus erythematosus (Discoid Lupus Erythematosus, DLE) and in generalized as well as deep forms of morphea. In addition, we reviewed the literature and current guidelines regarding treatment of both diseases.

Get Citation

Keywords

methotrxate; autoimmune connective tissue diseases; morphea; dyscoid lupus erthematosus; DLE

About this article
Title

The use of methotrexate in the treatment of selected autoimmune connective tissue diseases — our own experience and review of the literature data

Journal

Forum Dermatologicum

Issue

Vol 2, No 4 (2016)

Article type

Case report

Pages

165-170

Published online

2017-02-14

Page views

380

Article views/downloads

2739

Bibliographic record

Forum Dermatologicum 2016;2(4):165-170.

Keywords

methotrxate
autoimmune connective tissue diseases
morphea
dyscoid lupus erthematosus
DLE

Authors

Adriana Polańska
Aleksandra Dańczak-Pazdrowska
Ryszard Żaba
Zygmunt Adamski

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
phone: +48 58 320 94 94, fax: +48 58 320 94 60, e-mail: viamedica@viamedica.pl